Furthermore, since the ex vivo expansion of TILs from TNBC sample was recently reported to be enhanced in the presence of 4–1BB agonistic antibody (against CD137, a TNF receptor superfamily member 9), it is possible that this approach could enhance TIL expansion from other breast tumor types [31]. This evidence concerns the gene TNFRSF9 and breast neoplasm.